CERo Therapeutics To Present CER-1236 Data Supporting Use In AML At Global Cell & Gene Therapy Summit 2024; Anticipates Initial Human Trials To Focus On AML Upon IND Clearance
Portfolio Pulse from Benzinga Newsdesk
CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) will present data on its lead compound CER-1236 at the Global Cell & Gene Therapy Summit 2024. The data supports the use of CER-1236 in treating acute myeloid leukemia (AML) and shows no adverse toxicities in healthy tissue. Initial human trials are anticipated upon IND clearance.
July 08, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CERo Therapeutics is presenting promising data on its lead compound CER-1236 for AML treatment at a major summit. The data shows effectiveness and safety, with initial human trials anticipated upon IND clearance.
The presentation of positive data on CER-1236 at a major summit and the anticipation of initial human trials upon IND clearance are likely to boost investor confidence and positively impact CERO's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100